Sino-Cuban joint venture Biotech Pharmaceutical Limited (BPL) has secured another indication approval in China for its biologic drug nimotuzumab, now authorized for the treatment of locally advanced head and neck squamous cell carcinoma (HNCC).
Nimotuzumab, an EGFR monoclonal antibody (mAb), previously received marketing approvals in China for nasopharyngeal carcinoma (NPC) in 2008 and for pancreatic cancer in 2023. This latest approval expands the drug’s therapeutic applications and underscores BPL’s commitment to addressing critical oncology needs in the region.- Flcube.com
